ASH 2022 | Outcomes of patients with AL amyloidosis after failure of daratumumab-based therapy
Efstathios Kastritis
• 11 Dec 2022
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, briefly discusses the outcomes of patients with light chain (AL) amyloidosis who progress on or do not respond to daratumumab-based therapy, and highlights options for these patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Honoraria; Takeda: Honoraria; Pfizer: Honoraria, Research Funding; Genesis Pharma: Honoraria; Janssen: Honoraria, Research Funding; Amgen: Honoraria, Research Funding.
